Polymorphisms of the 5-HT2A receptor gene and clinical response to olanzapine in paranoid schizophrenia

Neuropsychobiology

Volumn 64, Issue 4, 2011, Pages 202-210

  Olajossy Hilkesberger, Luiza ^a   Godlewska, Beata ^c   Schosser Haupt, Alexandra ^a   Olajossy, Marcin ^a   Wojcierowski, Jacek ^b   Landowski, Jerzy ^c   Marmurowska Michałowska, Halina ^a   Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

5 HT2A receptor gene; Olanzapine; Paranoid schizophrenia; Positive and Negative Syndrome Scale

Indexed keywords

OLANZAPINE; SEROTONIN 2A RECEPTOR;

ADULT; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, SEROTONIN, 5-HT2A; SCHIZOPHRENIA, PARANOID; SEX CHARACTERISTICS;

EID: 80052737679     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000327602     Document Type: Review

References (35)

1. Propping P, Nöthen MM: Genetic variation of CNS receptors -A new perspective for pharmacogenetics. Pharmacogenetics 1995; 5: 318-325.
2. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch KP, Meyer JF, Sham P, Collier DA, Murray RM, Kerwin RW: Pharmacogenetic prediction of clozapine response. Lancet 2000; 355: 1615-1616. (Pubitemid 30240510)
3. Aghajanian GK, Marek GJ: Serotonin and hallucinogens. Neuropsychopharmacology 1999; 21: 16S-23S. (Pubitemid 29396466)
4. Meltzer HY, Matsubara S, Lee JC: The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25: 390-392. (Pubitemid 20260244)
5. Warren JT Jr, Peacock ML, Rodrigues LC, Fink JK: An MspI polymorphism in the human serotonin receptor gene (HTR2): Detection by DGGE and RFLP analysis. Hum Mol Genet 1993; 2: 338. (Pubitemid 23129111)
6. Erdmann J, Shimron-Abarbanell D, Rietschel M, Albus M, Maier W, Korner J, Bondy B, Chen K, Shih JC, Knapp M, Propping P, Nothen MM: Systematic screening for mutations in the human serotonin-2A (5HT2A) receptor gene: Identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet 1996; 97: 614-619.
7. Spurlock G, Heils A, Holmans P, Williams J, D'Souza UM, Cardno A, Murphy KC, Jones L, Buckland PR, McGuffin P, Lesch KP, Owen MJ: A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry 1998; 3: 42-49. (Pubitemid 28045184)
8. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, Sham P, Kerwin R: Association between clozapine response and allelic variation in 5HT2A receptor gene. Lancet 1995; 346: 281-282.
9. Masellis M, Paterson AD, Badri F, Lieberman JA, Meltzer HY, Cavazzoni P, Kennedy JL: Genetic variation of the 5HT2A receptor and response to clozapine. Lancet 1995; 346: 1108.
10. Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, Cola P, Howard A, Badri F, Noethen MM, Kalow W, Kennedy JL: Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998; 19: 123-132. (Pubitemid 28288438)
11. Nothen MM, Rietschel M, Erdmann J, Oberlander H, Moller HJ, Nober D, Propping P: Genetic variation of the 5HT2A receptor and response to clozapine. Lancet 1995; 346: 908-909.
12. Malhotra AK, Goldman D, Ozaki N, Breier A, Buchanan R, Pickar D: Lack of association between polymorphisms in the 5HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry 1996; 153: 1092-1094. (Pubitemid 26264713)
13. Arranz MJ, Munro J, Sham P, Kirov G, Murray RM, Collier DA, Kerwin RW: Metaanalysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998; 32: 93-99. (Pubitemid 28364714)
14. Arranz MJ, Munro J, Owen MJ, Spurlock G, Sham PC, Zhao J, Kirov G, Collier DA, Kerwin RW: Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A-receptor gene and response to clozapine. Mol Psychiatry 1998; 3: 61-66. (Pubitemid 28045186)
15. Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH: Association of risperidone treatment response with a polymorphism in the 5HT2A receptor gene. Am J Psychiatry 2002; 195: 1593-1595.
16. Ellingrod VL, Perry PJ, Lund BC, Bever-Stille K, Fleming F, Holman TL, Miller D: 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia. J Clin Psychopharmacol 2002; 22: 622-624. (Pubitemid 35416790)
17. Rietschel M, Kennedy JL, Macciardi F, Meltzer HY, The Consensus Group for Outcome Measures in Psychoses for Pharmacological Studies: Application of pharmacogenetics to psychotic disorders: The first consensus conference. Schizophr Res 1999; 37: 191-196.
18. Lane HY, Hsu S, Liu Y, Chang Y, Huang C, Chang W: Dopamine D 3 receptor Sre9Gly polymorphism and risperidone response. J Clin Psychopharmacol 2005; 25: 6-11. (Pubitemid 40129376)
19. Reynolds GP, Yao Z, Zhang X, Sun J, Zhang Z: Pharmacogenetics of treatment in firstepisode schizophrenia; D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 2005; 15: 143-151. (Pubitemid 40193419)
20. Kay SR, Opler LA, Lindenmayer JP: The Positive and Negative Syndrome Scale (PANSS): Rationale and standardisation. Br J Psychiatry Suppl 1989; 7: 59-67.
21. Olajossy M, Masiak M, Jarema M, Rabe-Jablonska J, Rybakowski J: Polish patients with I episode of schizophrenia in EUFEST study: Change of the psychopathology level depending on the antipsychotic medication used. Pharmakother Psychiatr Neurol 2009; 2: 85-93.
22. Ozaki N, Manji H, Lubierman V, Lu SJ, Lappalainen J, Rosenthal NE, Goldman D: A naturally occurring amino acid substitution of the human serotonin 5HT2A receptor influences amplitude and timing of intracellular calcium mobilization. J Neurochem 1997; 68: 2186-2193. (Pubitemid 27176157)
23. Arranz M, Collier D, Munro J, Sham P, Kirov G, Sodhi M, Roberts G, Price J, Kerwin R: Analysis of a structural polymorphism in the 5HT2A receptor and clinical response to clozapine. Neurosci Lett 1996; 217: 177-178. (Pubitemid 26358831)
24. Parsons MJ, D'Souza UM, Arranz MJ, Kerwin RW, Makoff AJ: The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry 2004; 56: 406-410. (Pubitemid 39195320)
25. Davies MA, Setola V, Strachan RT, Sheffler DJ, Salay E, Hufeisen SJ, Roth BL: Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenomics J 2006; 6: 42-51. (Pubitemid 43118310)
26. Gunes A, Melkersson KI, Scordo MG, Dahl ML: Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol 2009; 29: 65-68.
27. Kato M, Fukuda T, Wakeno M, Fukuda K, Okugawa G, Ikenaga Y, Yamashita M, Takekita Y, Nobuhara K, Azuma J, Kinoshita T: Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006; 53: 186-195. (Pubitemid 44252779)
28. Williams J, McGuffin P, Nothen M, Owen MJ: Meta-analysis of association between the 5HT2A receptor T102C polymorphism and schizophrenia. Lancet 1997; 349: 1221. (Pubitemid 27190050)
29. Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T, Kodama M, Ishihara T, Kuroda S: Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: A cohort study. J Clin Psychiatry 2008; 69: 1416-1422
30. Joober R, Benkelfat C, Brisebois K, Toulouse A, Turecki G, Lal S, Bloom D, Labelle A, Lalonde P, Fortin D, Alda M, Palmour R, Rouleau GA: T102C polymorphism in the 5HT2A gene and schizophrenia: Relation to phenotype and drug response variability. J Psychiatry Neurosci 1999; 24: 141-146.
31. Alenius M, Wadelius M, Dahl ML, Hartvig P, Lindstrom L, Hammarlund-Udenaes M: Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatr Res 2008; 42: 884-893.
32. Thomas P, Srivastava V, Singh A, Mathur P, Nimgaonkar VL, Lerer B, Thelma BK, Deshpande SN: Correlates of response to olanzapine in a North Indian schizophrenia sample. Psychiatry Res 2008; 161: 275-283.
33. Young MA, Meltzer HY: The relationship of demographic, clinical and outcome variables to neuroleptic treatment requirements. Schizophr Bull 1980; 6: 88-101. (Pubitemid 10066396)
34. Seeman MV: Interaction of sex, age and neuroleptic dose. Compr Psychiatry 1983; 24: 125-128. (Pubitemid 13079410)
35. Kolakowska T, Williams AO, Ardren M, Reverly MA, Jambor K, Gedler MG, Mandelbrote BM: Schizophrenia with good and poor outcome. 1. Early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 1985; 146: 229-239.